Literature DB >> 2076385

The effect of captopril on peripheral hemodynamics in patients with essential hypertension: comparison between oral and sublingual administration.

C Longhini1, L Ansani, G Musacci, D Mele, M Vaccari, E Baracca, P Sgobino.   

Abstract

A comparative study of the effects of oral and sublingual captopril on the hemodynamics of the peripheral musculocutaneous vasculature was carried out on ten patients with essential hypertension. Both routes of administration of captopril lead to lower blood pressure and decreased regional resistance, and to an increased arterial blood flow at rest. The first measurable effect and the peak effect on blood pressure and peripheral hemodynamics appear slightly earlier with sublingual administration. The data provided in this study support the usefulness of the sublingual route in clinical situations in which oral administration of captopril is not feasible.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2076385     DOI: 10.1007/BF01856565

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  21 in total

1.  Pharmacokinetics of captopril and its effects on blood pressure during acute and chronic administration and in relation to food intake.

Authors:  K P Ohman; B Kågedal; R Larsson; B E Karlberg
Journal:  J Cardiovasc Pharmacol       Date:  1985       Impact factor: 3.105

2.  Sublingual captopril in hypertensive crisis.

Authors:  W Tschollar; G G Belz
Journal:  Lancet       Date:  1985-07-06       Impact factor: 79.321

3.  Captopril in hypertensive crisis.

Authors:  J H Hauger-Klevene
Journal:  Lancet       Date:  1985-09-28       Impact factor: 79.321

4.  Comparison of sublingual captopril and nifedipine.

Authors:  J H Hauger-Klevene
Journal:  Lancet       Date:  1986-01-25       Impact factor: 79.321

5.  Hypertensive emergencies in old age: effects of angiotensin converting enzyme inhibition.

Authors:  V Marigliano; D Santilli; M Fiorani; A Ariani; M Cacciafesta; C Ferri; G Piccirillo
Journal:  J Hypertens Suppl       Date:  1988-11

6.  Comparison of sublingual and oral captopril in hypertension.

Authors:  P Dessì-Fulgheri; F Bandiera; S Rubattu; F Cocco; P Madeddu; M Oppes; G C Tonolo; N Glorioso; A Rappelli
Journal:  Clin Exp Hypertens A       Date:  1987

7.  Captopril in hypertension; seven years later.

Authors:  A C Jenkins; G R Dreslinski; S S Tadros; J T Groel; R Fand; S A Herczeg
Journal:  J Cardiovasc Pharmacol       Date:  1985       Impact factor: 3.105

8.  Pre- and postjunctional inhibition of vascular sympathetic function by captopril in SHR. Implication of vascular angiotensin II in hypertension and antihypertensive actions of captopril.

Authors:  M J Antonaccio; L Kerwin
Journal:  Hypertension       Date:  1981 May-Jun       Impact factor: 10.190

9.  The effects of captopril on blood pressure in essential hypertensive patients with low or normal plasma renin activity. Interference with autonomic nervous system.

Authors:  E Degli Esposti; C Chiarini; A Masi; A Santoro; A Sturani; A Umile; A Zuccalà; P Zucchelli
Journal:  Clin Exp Hypertens       Date:  1981       Impact factor: 1.749

10.  Acute and chronic converting enzyme inhibition reduces the vasomotor response to reflex sympathetic activation in man.

Authors:  A Morganti; G Grassi; C Sala; A Capozi; L Turolo; E Sabadini; G Bolla; G Mancia; A Zanchetti
Journal:  J Hypertens Suppl       Date:  1985-12
View more
  2 in total

Review 1.  Clinical pharmacokinetics of drug administered buccally and sublingually.

Authors:  J G Motwani; B J Lipworth
Journal:  Clin Pharmacokinet       Date:  1991-08       Impact factor: 6.447

2.  A pharmacokinetic and pharmacodynamic evaluation of buffered sublingual captopril in patients with congestive heart failure.

Authors:  J C McElnay; T A al-Furaih; C M Hughes; M G Scott; D P Nicholls
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.